Biosmallcap

micro cap biotech
less is more

[Biosmallcap @RachitJ3]

$NCEL feedback from the FDA meeting due.
$PCSA as per lastest 10Q
Phase 2 trial of NGC-Cap in advanced or metastatic breast cancer enrolled and dosed 20 patients required for the planned first interim analysis, which is expected to be completed in the first half of 2026.

[Biosmallcap @RachitJ3]

@earthling_777 @RaffaeleDi72001 What news are you expecting in July? Thanks

[Biosmallcap @RachitJ3]

@Dogtor01416800 Current cash runway expected to extend through Q3 2026. NMIBC Phase 2 data read out Q4 2026 as per latest presentation.

[Biosmallcap @RachitJ3]

$HCWB 51% short - over 3M shares. company hired 2 investor relations firm for 3M recently, Data due anyday.
$KTTA data due in June, eligible for PRV worth 200M. Decent cash and institution ownership.

[Biosmallcap @RachitJ3]

$HCWB Phase 1 data due in 2 weeks.
Contracted 2 IR firms worth 3M
CTB 700%
$VRAX PAIS data due in Q2.

[Biosmallcap @RachitJ3]

@Dogtor01416800 Great call mate, sold all for now.

[Biosmallcap @RachitJ3]

@Muramasatrades MNPR sold all around 14, there will be a couple more this year too in micro cap biotech lets see.

[Biosmallcap @RachitJ3]

$HCWB Trial started in November'25 data due within 30-45 days.
$JUNS Parkinson's trial update due in april.
$GLMD decent cash position news due soon.

[Biosmallcap @RachitJ3]

@EmiratesSupport @smeeagain48 Hi, DM won't work can you contact me by DM please about my flight departing tomorrow.
many thanks!

[Biosmallcap @RachitJ3]

@EmiratesSupport @farglator Hi, DM won't work can you contact me by DM please about my flight departing tomorrow.
many thanks!

[Biosmallcap @RachitJ3]

@crypto1nfern0 sold $AIM early stage data, low on cash. I’ll revisit later. $ADGM is still my number one play for April data - Very likely to be positive.

[Biosmallcap @RachitJ3]

$AIM congrats if you got it in last month! probably goes higher, take profit as always!
$ADGM $AEMD adding to core position.

[Biosmallcap @RachitJ3]

$AIM strategic focus on pancreatic cancer trial data due in 2 weeks.
mid-year review was positive. AstraZeneca headline would be great!
$ADGM adding slowly for April data.

[Biosmallcap @RachitJ3]

@Dogtor01416800 like the setup, low float and no imminent offering risk.
ER next week I’ll re-consider adding after an update from them.

[Biosmallcap @RachitJ3]

$AIM strategic focus on pancreatic cancer trial data due in 2 weeks.
mid-year review was positive. AstraZeneca headline would be great!
$ADGM adding slowly for April data.

[Biosmallcap @RachitJ3]

@ElMonoGran42994 too many fluff pr's lol

[Biosmallcap @RachitJ3]

$ENVB out for now on the patent news pop

[Biosmallcap @RachitJ3]

$XCUR swing paying well!
$AIM data due Ampligen and Astra Zeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi – or durvalumab – in the treatment of metastatic pancreatic cancer update by the end of the current quarter.
$ENVB $TCRT news due any day.

[Biosmallcap @RachitJ3]

$XCUR let's see if we get a PR after hours or tomorrow.
Date and Time: December 8, 2025, 5:45-6:00 pm EST $GLTO

[Biosmallcap @RachitJ3]

@SupNovaTrading $XCUR* not PBM

[Biosmallcap @RachitJ3]

$AIM Warrants at 4, Astra zeneca headline should do it.

[Biosmallcap @RachitJ3]

$XCUR let's see if we get a PR after hours or tomorrow.
Date and Time: December 8, 2025, 5:45-6:00 pm EST $GLTO